A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis-Reference-Cited by-同舟云学术

A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis

Published:2020-10 Issue:5 Volume:59 Page:102819
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Laszlo D.,Marcacci GP.,Martino M.,Radice D.,Rabascio C.,Lucchetti B.,Magarò A.,Caime A.,Menna S.,Lionetti MT.,Bertolini F.

Funder

Sanoﬁ for the additional costs of the trial

Publisher

Elsevier BV

Subject

Hematology

Reference17 articles.

1. Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?;Engelhardt;Haematologica,2019

2. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial;Bringhen;Haematologica,2019

3. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial;Wester;Haematologica,2019

4. Autologous stem cell transplantation versus Bortezomib-Melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02/HO95 study;Cavo;Blood,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining external control arms in oncology: A scoping review of applications to date;Cancer Medicine;2024-07

2. Steady-State Versus Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma: A Single-Center Study to Analyze Efficacy and Safety;Journal of Hematology;2024-06

3. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G‐CSF versus G‐CSF only: A single‐center retrospective analysis;Transfusion;2024-04-10

4. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost;Frontiers in Oncology;2024-01-17

5. Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients;Cytotherapy;2023-08